In the KIRC-TCGA cohort, increased IL34 expression was associated with reduced survival in RCC patients (Figure 1A), increased tumor grade, and increased incidence of distant metastases (Figures 1B and 1C). This evidence concerns the gene IL34 and renal cell carcinoma.